290 related articles for article (PubMed ID: 14742188)
1. Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir.
Quenelle DC; Collins DJ; Wan WB; Beadle JR; Hostetler KY; Kern ER
Antimicrob Agents Chemother; 2004 Feb; 48(2):404-12. PubMed ID: 14742188
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of multiple- or single-dose cidofovir against vaccinia and cowpox virus infections in mice.
Quenelle DC; Collins DJ; Kern ER
Antimicrob Agents Chemother; 2003 Oct; 47(10):3275-80. PubMed ID: 14506041
[TBL] [Abstract][Full Text] [Related]
3. Oral treatment of murine cytomegalovirus infections with ether lipid esters of cidofovir.
Kern ER; Collins DJ; Wan WB; Beadle JR; Hostetler KY; Quenelle DC
Antimicrob Agents Chemother; 2004 Sep; 48(9):3516-22. PubMed ID: 15328119
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous infections of mice with vaccinia or cowpox viruses and efficacy of cidofovir.
Quenelle DC; Collins DJ; Kern ER
Antiviral Res; 2004 Jul; 63(1):33-40. PubMed ID: 15196818
[TBL] [Abstract][Full Text] [Related]
5. Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir.
Kern ER; Hartline C; Harden E; Keith K; Rodriguez N; Beadle JR; Hostetler KY
Antimicrob Agents Chemother; 2002 Apr; 46(4):991-5. PubMed ID: 11897580
[TBL] [Abstract][Full Text] [Related]
6. Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.
Quenelle DC; Collins DJ; Herrod BP; Keith KA; Trahan J; Beadle JR; Hostetler KY; Kern ER
Antimicrob Agents Chemother; 2007 Nov; 51(11):3940-7. PubMed ID: 17846137
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model.
Buller RM; Owens G; Schriewer J; Melman L; Beadle JR; Hostetler KY
Virology; 2004 Jan; 318(2):474-81. PubMed ID: 14972516
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory activity of alkoxyalkyl and alkyl esters of cidofovir and cyclic cidofovir against orthopoxvirus replication in vitro.
Keith KA; Wan WB; Ciesla SL; Beadle JR; Hostetler KY; Kern ER
Antimicrob Agents Chemother; 2004 May; 48(5):1869-71. PubMed ID: 15105146
[TBL] [Abstract][Full Text] [Related]
9. Intranasal treatment of cowpox virus respiratory infections in mice with cidofovir.
Smee DF; Bailey KW; Wong M; Sidwell RW
Antiviral Res; 2000 Sep; 47(3):171-7. PubMed ID: 10974369
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, metabolic stability and antiviral evaluation of various alkoxyalkyl esters of cidofovir and 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine.
Ruiz J; Beadle JR; Buller RM; Schreiwer J; Prichard MN; Keith KA; Lewis KC; Hostetler KY
Bioorg Med Chem; 2011 May; 19(9):2950-8. PubMed ID: 21493074
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and antiviral evaluation of alkoxyalkyl-phosphate conjugates of cidofovir and adefovir.
Ruiz JC; Beadle JR; Aldern KA; Keith KA; Hartline CB; Kern ER; Hostetler KY
Antiviral Res; 2007 Jul; 75(1):87-90. PubMed ID: 17367874
[TBL] [Abstract][Full Text] [Related]
12. Treatment of lethal cowpox virus respiratory infections in mice with 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine and its orally active diacetate ester prodrug.
Smee DF; Bailey KW; Sidwell RW
Antiviral Res; 2002 May; 54(2):113-20. PubMed ID: 12062396
[TBL] [Abstract][Full Text] [Related]
13. Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses.
Smee DF; Sidwell RW; Kefauver D; Bray M; Huggins JW
Antimicrob Agents Chemother; 2002 May; 46(5):1329-35. PubMed ID: 11959564
[TBL] [Abstract][Full Text] [Related]
14. Oral activity of ether lipid ester prodrugs of cidofovir against experimental human cytomegalovirus infection.
Bidanset DJ; Beadle JR; Wan WB; Hostetler KY; Kern ER
J Infect Dis; 2004 Aug; 190(3):499-503. PubMed ID: 15243923
[TBL] [Abstract][Full Text] [Related]
15. Treatment of lethal vaccinia virus respiratory infections in mice with cidofovir.
Smee DF; Bailey KW; Sidwell RW
Antivir Chem Chemother; 2001 Jan; 12(1):71-6. PubMed ID: 11437324
[TBL] [Abstract][Full Text] [Related]
16. Comparative effects of cidofovir and cyclic HPMPC on lethal cowpox and vaccinia virus respiratory infections in mice.
Smee DF; Bailey KW; Sidwell RW
Chemotherapy; 2003 Jun; 49(3):126-31. PubMed ID: 12815205
[TBL] [Abstract][Full Text] [Related]
17. Effects of cidofovir on the pathogenesis of a lethal vaccinia virus respiratory infection in mice.
Smee DF; Bailey KW; Wong MH; Sidwell RW
Antiviral Res; 2001 Oct; 52(1):55-62. PubMed ID: 11530188
[TBL] [Abstract][Full Text] [Related]
18. Increased antiviral activity of 1-O-hexadecyloxypropyl-[2-(14)C]cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism.
Aldern KA; Ciesla SL; Winegarden KL; Hostetler KY
Mol Pharmacol; 2003 Mar; 63(3):678-81. PubMed ID: 12606777
[TBL] [Abstract][Full Text] [Related]
19. Effects of four antiviral substances on lethal vaccinia virus (IHD strain) respiratory infections in mice.
Smee DF; Wong MH; Bailey KW; Beadle JR; Hostetler KY; Sidwell RW
Int J Antimicrob Agents; 2004 May; 23(5):430-7. PubMed ID: 15120719
[TBL] [Abstract][Full Text] [Related]
20. Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney.
Ciesla SL; Trahan J; Wan WB; Beadle JR; Aldern KA; Painter GR; Hostetler KY
Antiviral Res; 2003 Aug; 59(3):163-71. PubMed ID: 12927306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
